Related Experiment Videos
Epidermal growth factor stimulates insulin-like growth factor-binding protein-1 expression in the neonatal rat
M A Murray1, B A Dickson, E P Smith
1Division of Endocrinology, Children's Hospital Medical Center, Cincinnati, Ohio 45229-2899.
Insights
Epidermal growth factor (EGF) administration to newborn rats rapidly increases insulin-like growth factor-binding protein 1 (IGFBP-1) levels, likely by stimulating its synthesis. This suggests elevated IGFBP-1 may inhibit growth in neonatal rats.
Area of Science:
- Endocrinology
- Developmental Biology
- Molecular Biology
Background:
- Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) regulate perinatal growth.
- Epidermal growth factor (EGF) administration inhibits neonatal rat pup growth and decreases serum IGF-I.
Purpose of the Study:
- To investigate the effect of EGF on IGFBPs in neonatal rats.
- To determine if EGF influences IGFBP-1 synthesis and serum concentrations.
Main Methods:
- Ligand blots of serum to analyze IGFBP concentrations.
- Northern analysis of hepatic RNA to assess IGFBP mRNA levels.
- Administration of EGF to newborn rat pups.
Main Results:
- EGF administration caused a rapid, 2-fold increase in serum IGFBP-1 concentration within 2 hours.
- Hepatic IGFBP-1 mRNA levels increased at least 2-fold by 2 hours and remained elevated for 4 hours.
- EGF specifically increased IGFBP-1; IGFBP-2 mRNA and serum IGFBP-3 and -4 concentrations were unaffected.
Conclusions:
- EGF administration stimulates IGFBP-1 synthesis and increases its serum concentration in neonatal rats.
- The increase in IGFBP-1 is independent of changes in serum insulin levels.
- Elevated IGFBP-1 concentrations following EGF treatment may restrict IGF bioactivity, contributing to growth inhibition.
Abstract:
Insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) appear to be important in the regulation of perinatal growth. We have shown previously that administration of epidermal growth factor (EGF) to newborn rat pups inhibits growth and decreases serum IGF-I concentrations. The experiments described here were designed to investigate the effect of EGF on the IGFBPs using ligand blots of serum and Northern analysis of hepatic RNA. EGF administration caused a rapid (within 2 h) 2-fold increase in the serum IGFBP-1 concentration. Hepatic IGFBP-1 mRNA increased even more rapidly, was increased at least 2-fold at 2 h, and remained elevated 4 h after EGF. The response to EGF was specific to IGFBP-1; IGFBP-2 hepatic mRNA content was not increased over the control value, and serum IGFBP-3 and -4 concentrations were not changed by ligand blot analysis. The IGFBP-1 response to EGF was most dramatic in the first few days of life. Although EGF lowered circulating insulin levels, EGF stimulated IGFBP-1 secretion in the presence of exogenously administered insulin. Thus, the increase in IGFBP-1 did not appear to be mediated by changes in serum insulin. These results demonstrate that EGF increases serum IGFBP-1 concentrations, probably by stimulating synthesis. The association of decreased growth and increased IGFBP-1 concentrations after EGF treatment suggests that elevated IGFBP-1 concentrations may restrict IGF bioactivity in the neonatal rat.